Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Low adherence to cervical cancer screening guidelines among women survivors after allogeneic hematopoietic cell transplantation: Predictors and practice gaps from a single-center analysis

Prajna Woonnimani, Amanda Bruegl, Haley Burns, Jessica Currier, Kate Bolten, Talia Frost-Belansky, Emily Van Houweling, Jennifer Saultz, Andy Chen, Jessica Leonard, Amrita Desai, Staci Williamson, Laura Newell, Brandon Hayes-Lattin, Gabrielle Meyers, Richard Maziarz, Rachel Cook, Arpita Gandhi

Blood (2025) 146 (Supplement 1): 7784.

https://doi.org/10.1182/blood-2025-7784

Published: 2025

Journal Articles

Comparison of 80 mg/kg vs. 100 mg/kg post-transplant cyclophosphamide dose with flu/mel and allogeneic transplant: Less is not more

Howard Chang, Staci Williamson, Daniel Chandra, Andy Chen, Rachel Cook, Amrita Desai, Arpita Gandhi, Brandon Hayes-Lattin, Curtis Lachowiez, Jessica Leonard, Richard Maziarz, Laura Newell, Jennifer Saultz, Ronan Swords, Elie Traer, Gabrielle Meyers

Blood (2025) 146 (Supplement 1): 4252.

https://doi.org/10.1182/blood-2025-4252

Published: 2025

Journal Articles

Large B-cell lymphoma after CD19-CAR-T failure: Updated real-world outcomes, prognostic factors, and prediction models

Smith Kungwankiattichai, Sanjog Bastola, Manoj Rai, Amrita Desai, Andy Chen, Craig Okada, Brandon Hayes-Lattin, Stephen Spurgeon, Tanaya Shree, Weerapat Owattanapanich, Staci Williamson, Bashi Ratterree, Rachel Bixler, Chi Phan, Robert Ahrenkiel, Richard Maziarz

Blood (2025) 146 (Supplement 1): 3726.

https://doi.org/10.1182/blood-2025-3726

Published: 2025

Journal Articles

High-dose anakinra to treat refractory immune effector cell-associated neurotoxicity syndrome in CAR T-cell therapy recipients

Blood (2025) 146 (Supplement 1): 928.

https://doi.org/10.1182/blood-2025-928

Published: 2025

Journal Articles

Novel composite end-points toxicity/progression-free survival (tfPFS) and toxicity-free complete remission (tfCR100) after CAR-T cell therapy for diffuse large B cell lymphoma: Cell therapy consortium analysis.

Veronika Bachanova, Qing Cao, Marie Hu, Supriya Gupta, Miguel-Angel Perales, Olalekan Oluwole, Richard Maziarz, Joseph McGuirk, Andy Chen, Stephen J. Schuster, Gunjan Shah, Anthony Hunter, Jamie Brower, David Porter, Peter Riedell

Blood (2025) 146 (Supplement 1): 400.

https://doi.org/10.1182/blood-2025-400

Published: 2025

Journal Articles

Comparable outcomes in patients aged ≥70 vs. <70 undergoing allogeneic transplantation with fludarabine and melphalan conditioning and post-transplant cyclophosphamide

Blood (2025) 146 (Supplement 1): 6085.

https://doi.org/10.1182/blood-2025-6085

Published: 2025

Journal Articles

Telehealth based virtual consult visits and in-person consult visits provide comparable time to HLA-typing and preliminary donor search in patients referred for allogeneic hematopoietic cell transplantation

Blood (2025) 146 (Supplement 1): 1083.

https://doi.org/10.1182/blood-2025-1083

Published: 2025

Journal Articles

FluMel100 with post-transplant cyclophosphamide: A safe and effective regimen for patients aged ≥75 years with MDS and AML

Blood (2025) 146 (Supplement 1): 7744.

https://doi.org/10.1182/blood-2025-7744

Published: 2025

Journal Articles

Clinical outcomes of tisagenlecleucel in patients with relapsed/refractory follicular lymphoma (r/r FL): Phase 2 ELARA 5-year update

Blood (2025) 146 (Supplement 1): 468.

https://doi.org/10.1182/blood-2025-468

Published: 2025

Journal Articles

Activity of autologous anti-CD19 chimeric antigen receptor T-cell therapy in CD19-negative large B-cell lymphoma: A cell therapy consortium real world experience

Chen Zhang, Xiaowen Sun, Lei Feng, David Porter, Stephen J. Schuster, Olalekan Oluwole, Veronika Bachanova, Supriya Gupta, Joseph McGuirk, Richard Maziarz, Andy Chen, Sairah Ahmed, Peter Riedell, Anthony Hunter, Paolo Strati

Blood (2025) 146 (Supplement 1): 957.

https://doi.org/10.1182/blood-2025-957

Published: 2025

Journal Articles

Interim analysis of safety and efficacy in a Phase 2 study of MB-105, a CD5.CAR T therapy for patients with relapsed/refractory T cell lymphoma

Blood (2025) 146 (Supplement 1): 775.

https://doi.org/10.1182/blood-2025-775

Published: 2025

Journal Articles

Optimizing processes for adverse event management for bispecific antibodies for diffuse large b-cell lymphoma in community practice: Insights from a quality improvement initiative

Krish Patel, Joshua Brody, M. Sarfraz Nawaz, Jeffrey Bubis, Andy Chen, Edward Pearson, Emily Zyborowicz, Jeffrey Carter, Cherilyn Heggen, Shelby Sullivan, Lindsay Gurska

Blood (2025) 146 (Supplement 1): 6183.

https://doi.org/10.1182/blood-2025-6183

Published: 2025

Journal Articles

CAR T Cell Therapy in Early Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium

Alexandra E. Rojek, Nausheen Ahmed, Marina Gomez Llobell, Sairah Ahmed, Marie Hu, Monica Mead, Andy Chen, Vivek Patel, Jamie Brower, Veronika Bachanova, Richard T. Maziarz, Olalekan O. Oluwole, Michael R Bishop, David L. Porter, Miguel Angel Perales, Joseph P. McGuirk, Peter A. Riedell, Daniel J. Landsburg

Blood (2024) 144 (Supplement 1): 4503.

https://doi.org/10.1182/blood-2024-198153

Published: 2024

Journal Articles

Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update

Blood (2024) 144 (Supplement 1): 3034.

https://doi.org/10.1182/blood-2024-201730

Published: 2024

Journal Articles

“Defining the Optimal Post-CART Monitoring Period in Recipients of Axicabtagene Ciloleucel and Tisagenlecleucel”

William Wesson, Forat Lutfi, David L. Porter, Veronika Bachanova, Loretta J. Nastoupil, Peter A. Riedell, Miguel-Angel Perales, Richard T Maziarz, Jamie Brower, Gunjan L. Shah, Andy Chen, Olalekan O. Oluwole, Stephen J Schuster, Michael R. Bishop, Joseph P McGuirk, Nausheen Ahmed

Blood (2023) 142 (Supplement 1): 4887.

https://doi.org/10.1182/blood-2023-182837

Published: 2023

Journal Articles

Access and Outcomes of Minority Health Populations Receiving Commercial Anti-CD19 CART Therapy for Non-Hodgkin Lymphoma

Blood (2023) 142 (Supplement 1): 2416.

https://doi.org/10.1182/blood-2023-187524

Published: 2023

Journal Articles

Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium

Peter A Riedell, Connor Grady, Loretta J. Nastoupil, Alejandro Luna, Nausheen Ahmed, Richard T Maziarz, Marie Hu, Jamie Brower, Wei-Ting Hwang, Stephen J Schuster, Andy Chen, Olalekan O. Oluwole, Veronika Bachanova, Joseph P McGuirk, Miguel-Angel Perales, Michael R. Bishop, David L. Porter

Blood (2023) 142 (Supplement 1): 617.

https://doi.org/10.1182/blood-2023-184862

Published: 2023

Journal Articles

Access to Chimeric Antigen T-Cell Receptor (CAR-T) Therapies for Patients with Non-Hodgkin Lymphoma (NHL) in the Catchment Area of Oregon

Somya Khare, Staci Williamson, Brittany O'Barr, Levanto Schachter, Andy Chen, Brandon Hayes-Lattin, Jessica T. Leonard, Amrita Desai, Peter Ferreira-Gandolfo, Denise Lackey, Kevin Christmas, Richard T Maziarz, Eneida R Nemecek

Blood (2023) 142 (Supplement 1): 2405.

https://doi.org/10.1182/blood-2023-177864

Published: 2023

Journal Articles

Clinical Outcomes of Patients with Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 Elara 3-Year Follow-up

Blood (2023) 142 (Supplement 1): 601.

https://doi.org/10.1182/blood-2023-180936

Published: 2023

Journal Articles

Predictors and Outcomes of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Aggressive B-Cell Non-Hodgkin Lymphoma

Vivek Patel, Shakthi Bhaskar, Stephen J. Schuster, Loretta J. Nastoupil, Miguel-Angel Perales, Roni Shouval, Joseph P. McGuirk, Richard T. Maziarz, Andy Chen, Veronika Bachanova, David L. Porter, Michael R. Bishop, Peter A. Riedell, Olalekan O. Oluwole

Blood (2022) 140 (Supplement 1): 366–368.

https://doi.org/10.1182/blood-2022-165556

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Low adherence to cervical cancer screening guidelines among women survivors after allogeneic hematopoietic cell transplantation: Predictors and practice gaps from a single-center analysis

Comparison of 80 mg/kg vs. 100 mg/kg post-transplant cyclophosphamide dose with flu/mel and allogeneic transplant: Less is not more

Large B-cell lymphoma after CD19-CAR-T failure: Updated real-world outcomes, prognostic factors, and prediction models

High-dose anakinra to treat refractory immune effector cell-associated neurotoxicity syndrome in CAR T-cell therapy recipients

Novel composite end-points toxicity/progression-free survival (tfPFS) and toxicity-free complete remission (tfCR100) after CAR-T cell therapy for diffuse large B cell lymphoma: Cell therapy consortium analysis.

Comparable outcomes in patients aged ≥70 vs. <70 undergoing allogeneic transplantation with fludarabine and melphalan conditioning and post-transplant cyclophosphamide

Telehealth based virtual consult visits and in-person consult visits provide comparable time to HLA-typing and preliminary donor search in patients referred for allogeneic hematopoietic cell transplantation

FluMel100 with post-transplant cyclophosphamide: A safe and effective regimen for patients aged ≥75 years with MDS and AML

Clinical outcomes of tisagenlecleucel in patients with relapsed/refractory follicular lymphoma (r/r FL): Phase 2 ELARA 5-year update

Activity of autologous anti-CD19 chimeric antigen receptor T-cell therapy in CD19-negative large B-cell lymphoma: A cell therapy consortium real world experience

Interim analysis of safety and efficacy in a Phase 2 study of MB-105, a CD5.CAR T therapy for patients with relapsed/refractory T cell lymphoma

Optimizing processes for adverse event management for bispecific antibodies for diffuse large b-cell lymphoma in community practice: Insights from a quality improvement initiative

CAR T Cell Therapy in Early Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium

Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update

“Defining the Optimal Post-CART Monitoring Period in Recipients of Axicabtagene Ciloleucel and Tisagenlecleucel”

Access and Outcomes of Minority Health Populations Receiving Commercial Anti-CD19 CART Therapy for Non-Hodgkin Lymphoma

Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium

Access to Chimeric Antigen T-Cell Receptor (CAR-T) Therapies for Patients with Non-Hodgkin Lymphoma (NHL) in the Catchment Area of Oregon

Clinical Outcomes of Patients with Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 Elara 3-Year Follow-up

Predictors and Outcomes of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Aggressive B-Cell Non-Hodgkin Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only